|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge.
|
18636014 |
2008 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 44-year-old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon-21 L858R point mutation on initial presentation.
|
28296233 |
2017 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A gefitinib-resistant point mutation (T790M) in exon 20 without gefitinib treatment was detected in 1 AAH and 1 adenocarcinoma.
|
17561305 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbored an in-frame deletion in exon 19 (heterozygous delE746-A750) of EGFR without a second mutation such as T790M in exon 20.
|
17618013 |
2007 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.
|
17649787 |
2007 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After 12 mo of treatment with icotinib, ovarian biopsy showed adenocarcinoma with CDX2(-), TTF-1(+++), PAX8(-), CK-7(+++), CK-20(++), and Ki67(15%+), accompanied with EGFR 19-del mutation and T790M mutation.
|
31363481 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation.
|
26003540 |
2015 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation.
|
26003540 |
2015 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation.
|
26003540 |
2015 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although 19-deletion and L858R were the most common EGFR mutations, there was no difference of EGFR mutation in pathological subtypes of adenocarcinoma.
|
27032467 |
2016 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although 19-deletion and L858R were the most common EGFR mutations, there was no difference of EGFR mutation in pathological subtypes of adenocarcinoma.
|
27032467 |
2016 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although 19-deletion and L858R were the most common EGFR mutations, there was no difference of EGFR mutation in pathological subtypes of adenocarcinoma.
|
27032467 |
2016 |
|
rs150423237
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An adenocarcinoma patient with JM R675Q had erlotinib, 150 mg daily, added following progression of disease on carboplatin and paclitaxel and had a partial response for 4 months.
|
28573640 |
2017 |